A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Objective
Primary Objective: To compare Overall Survival (OS) and Recurrence Free Survival (RFS) as co-primary endpoints across the two arms.
Secondary Objective: To evaluate adverse events. To evaluate Distant Metastasis Free Survival (DMFS). To evaluate the impact of radiation on clinical outcomes (OS, RFS, DMFS).
